Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diagnostics in China

This article was originally published in The Gray Sheet

Executive Summary

China Medical Technologies broadens its in vitro diagnostic market presence in China through the purchase of Beijing Bio-Ekon Biotechnology for $28.8 million, announced Nov. 26. The acquired firm offers enzyme-linked immunosorbent assays and semi-automatic, enhanced chemiluminescence immunoassay (ECLIA) analyzers and related reagents in China, and expects to seek approval in China next year for a fully automatic version. CMT, which also offers ECLIA products, acquired fluorescent in situ hybridization diagnostics technology in February (1"The Gray Sheet" Feb. 12, 2007, p. 8)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel